Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells

Acta Pharmacologica Sinica

Volumn 32, Issue 2, 2011, Pages 259-269

  Wu, Xue Mei ^a,c   Shao, Xiang Qiang ^a,c   Meng, Xian Xin ^b   Zhang, Xiao Na ^b   Zhu, Li ^a   Liu, Shi Xu ^a,c   Lin, Jian ^a,c   Xiao, Hua Sheng ^a,b  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

cluster analysis; drug resistance; gastric cancer; gene expression regulation; hydroxycamptothecin (HCPT); messenger RNA; microRNA; signature

Indexed keywords

10 HYDROXYCAMPTOTHECIN; MESSENGER RNA; MICRORNA; MICRORNA 126; MICRORNA 196A; MICRORNA 200; MICRORNA 31; MICRORNA 338; MICRORNA 7; MICRORNA 98; PROTEIN BAX; PROTEIN RAD1; PROTEIN VSNL 1; SULFORHODAMINE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 79551669217     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.204     Document Type: Article

References (31)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-62.
2. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
3. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung 2008; 58: 261-4.
4. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145-67.
5. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
6. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008; 83: 673-91.
7. Beretta GL, Perego P, Zunino F. Mechanisms of cellular resistance to camptothecins. Curr Med Chem 2006; 13: 3291-305.
8. Saleem A, Edwards TK, Rasheed Z, Rubin H. Mechanisms of resistance to camptothecins. Ann N Y Acad Sci 2000; 922: 46-55.
9. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 2003; 22: 7296-304.
10. Lee YS, Dutta A. MicroRNAs: small but potent oncogees or tumor suppressors. Curr Opin Investig Drugs 2006; 7: 560-4.
11. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005; 11: 712-4.
12. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008; 452: 1-10.
13. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999-3004.
14. Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics 2007; 8: 1625-7.
15. Wu XM, Xiao HS. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009; 52: 797-801.
16. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9.
17. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 2007; 10: 59-67.
18. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007; 6: 1483-91.
19. Salter KH, Achar ya CR, Walters KS, Redman R, Anguiano A, Garman KS, et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008; 3: e1908.
20. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
21. Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. J Gastroenterol 2009; 44: 556-61.
22. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008; 68: 3566-72.
23. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009; 284: 5731-41.
24. Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol 2010; 27: 685-9.
25. Li X, Zhang Y, Zhang Y, Ding J, Wu K, Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010; 59: 579-85.
26. Wang Y, Lee CG. MicroRNA and cancer-focus on apoptosis. J Cell Mol Med 2009; 13: 12-23.
27. Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7: 1234-43.
28. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15: 2089-96.
29. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009; 273: 233-42.
30. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55: 2545-51.
31. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, et al. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 2004; 109: 848-54.